Evicenter
MarkdownMedical informationP&T meetings
VK2735

Chronic weight management

Last updated
184 sources

Section 5 of 6

Economic information and modeling report

21 evidence topics · 12 sources

Modeling overview

Summary

No published cost-effectiveness analysis, budget impact model, or announced price exists for VK2735; the evaluations below describe the incretin-based anti-obesity medications it would join. The ICER final evidence report of December 2025 modeled injectable semaglutide, oral semaglutide (at an assumed price equal to that of injectable semaglutide), and tirzepatide, each added to lifestyle modification, over a lifetime horizon from the health care sector perspective. At annual net prices of $6,829 for semaglutide and $7,973 for tirzepatide, the incremental cost-effectiveness ratios versus lifestyle modification were $57,779 per QALY gained for tirzepatide, $66,355 for injectable semaglutide, and $75,456 for oral semaglutide, and no discount was needed to reach the health benefit price benchmark of any of the three. ICER estimated about 92 million eligible U.S. adults and found that fewer than 1% could be treated within five years before its $880 million annual budget impact threshold was crossed, including at a Medicare price of $245 per month, and issued an access and affordability alert.

Other U.S. analyses reached different conclusions depending on the drug price and the perspective. The ICER 2022 assessment (semaglutide $237,000 per QALY gained) and a 2025 lifetime microsimulation (tirzepatide $197,023 and semaglutide $467,676 per QALY gained) found the GLP-1-based drugs not cost-effective at the net prices then assumed. A 30-year U.S. third-party payer model found semaglutide 2.4 mg cost-effective against all comparators at $150,000 per QALY gained, and a societal-perspective model based on SURMOUNT-5 found tirzepatide less costly and more effective than semaglutide. For Medicare, CBO estimated that authorizing coverage of anti-obesity medications would increase net federal spending by about $35 billion from 2026 to 2034, with a direct federal cost of about $5,600 per user in 2026, and a separate analysis estimated $3.1 billion to $6.1 billion in added annual Part D costs at 5% to 10% uptake among newly eligible beneficiaries. The CMS Medicare GLP-1 Bridge demonstration provides certain GLP-1 drugs to eligible Part D beneficiaries for a $50 copay from July 1, 2026, to December 31, 2027. In 2025, 19% of firms with 200 or more workers, and 43% of firms with 5,000 or more workers, covered GLP-1 agonists for weight loss.

Product-specific economic evaluation of VK2735

No evidence found.

Federal budgetary effects of authorizing Medicare coverage of anti-obesity medications

Budget impact model

Approach and framework

No evidence found.

Perspective and time frame

No evidence found.

Epidemiology and eligible population inputs

No evidence found.

Cost assumptions

No evidence found.

Model outcomes

No evidence found.

Results

Base case

No evidence found.

Scenario analyses

No evidence found.

Budget impact model discussion

No evidence found.